$12.56
2.78% day before yesterday
Nasdaq, Oct 03, 10:04 pm CET
ISIN
CA60255C1095
Symbol
MNMD

Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock price

$12.56
+3.50 38.63% 1M
+7.01 126.31% 6M
+5.60 80.46% YTD
+7.10 129.83% 1Y
+9.25 279.46% 3Y
+2.36 23.14% 5Y
-14.38 53.38% 10Y
-14.38 53.38% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
+0.34 2.78%
ISIN
CA60255C1095
Symbol
MNMD
Industry

Key metrics

Basic
Market capitalization
$955.7m
Enterprise Value
$813.9m
Net debt
positive
Cash
$183.0m
Shares outstanding
75.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.2
Financial Health
Equity Ratio
79.9%
Return on Equity
-45.0%
ROCE
-57.4%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-130.3m | $-154.5m
EBIT
$-130.3m | $-162.0m
Net Income
$-114.5m | $-137.9m
Free Cash Flow
$-101.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-47.4% | -49.4%
EBIT
-44.0% | -55.9%
Net Income
-12.2% | -26.9%
Free Cash Flow
-37.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.3
FCF per Share
$-1.3
Short interest
14.2%
Employees
74
Rev per Employee
$0.0
Show more

Is Mind Medicine Inc - Ordinary Shares (Sub Voting) a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Mind Medicine Inc - Ordinary Shares (Sub Voting) forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Mind Medicine Inc - Ordinary Shares (Sub Voting) forecast:

Buy
94%
Hold
6%

Financial data from Mind Medicine Inc - Ordinary Shares (Sub Voting)

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 32 32
7% 7%
-
- Research and Development Expense 98 98
83% 83%
-
-130 -130
47% 47%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -130 -130
44% 44%
-
Net Profit -115 -115
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mind Medicine Inc - Ordinary Shares (Sub Voting) directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock News

Neutral
Business Wire
13 days ago
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 182,800 common shares of the Compa...
Neutral
Business Wire
16 days ago
NEW YORK--(BUSINESS WIRE)--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented results from a cross-sectional retrospective study of more than 75,000 respondents from the 2022 National Health and Wellness Survey at the Psych...
Neutral
Business Wire
27 days ago
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of options to purchase an aggregate of 78,750 common shares of t...
More Mind Medicine Inc - Ordinary Shares (Sub Voting) News

Company Profile

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Head office Canada
CEO Robert Barrow
Employees 74
Founded 2019
Website ir.mindmed.co

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today